José Trigo

10.6k total citations · 1 hit paper
165 papers, 5.8k citations indexed

About

José Trigo is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, José Trigo has authored 165 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Oncology, 74 papers in Pulmonary and Respiratory Medicine and 41 papers in Molecular Biology. Recurrent topics in José Trigo's work include Lung Cancer Treatments and Mutations (49 papers), Lung Cancer Research Studies (28 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). José Trigo is often cited by papers focused on Lung Cancer Treatments and Mutations (49 papers), Lung Cancer Research Studies (28 papers) and Neurotransmitter Receptor Influence on Behavior (23 papers). José Trigo collaborates with scholars based in Spain, United States and France. José Trigo's co-authors include Ricardo Hitt, Nadia Amellal, Rafaël Maldonado, José Baselga, Patricia Robledo, Frédéric Rolland, Eduardo Díaz‐Rubio, Rainald Knecht, P. Koralewski and Bernard Le Foll and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and PLoS ONE.

In The Last Decade

José Trigo

159 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy

2007 734 citations José Trigo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
José Trigo Spain	38	2.6k	1.6k	1.6k	1.1k	856	165	5.8k
Jennifer M. Johnson United States	25	847 0.3×	364 0.2×	612 0.4×	170 0.2×	306 0.4×	104	2.3k
Willem Boogerd Netherlands	54	3.2k 1.2×	6.8k 4.1×	861 0.6×	90 0.1×	159 0.2×	135	9.7k
Jacqueline P. Williams United States	42	750 0.3×	2.3k 1.4×	1.1k 0.7×	162 0.1×	84 0.1×	115	5.5k
David Gillatt United Kingdom	40	1.1k 0.4×	1.8k 1.1×	1.7k 1.1×	389 0.3×	231 0.3×	163	5.6k
Katsuya Maruyama Japan	39	432 0.2×	654 0.4×	1.4k 0.9×	212 0.2×	178 0.2×	190	4.9k
Jeffrey P. Greenfield United States	34	307 0.1×	232 0.1×	976 0.6×	399 0.4×	964 1.1×	143	4.7k
Isabelle M. Germano United States	44	660 0.3×	567 0.3×	2.7k 1.7×	252 0.2×	1.2k 1.4×	163	8.0k
Takayuki Yamamoto Japan	54	846 0.3×	435 0.3×	1.7k 1.1×	357 0.3×	588 0.7×	271	8.9k
D Müller Germany	32	634 0.2×	118 0.1×	1.1k 0.7×	336 0.3×	368 0.4×	86	3.5k
Yukiko Nakamura Japan	34	1.2k 0.4×	1.2k 0.7×	799 0.5×	81 0.1×	201 0.2×	183	3.7k

Countries citing papers authored by José Trigo

Since Specialization

Citations

This map shows the geographic impact of José Trigo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Trigo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Trigo more than expected).

Fields of papers citing papers by José Trigo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José Trigo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Trigo. The network helps show where José Trigo may publish in the future.

Co-authorship network of co-authors of José Trigo

This figure shows the co-authorship network connecting the top 25 collaborators of José Trigo. A scholar is included among the top collaborators of José Trigo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Trigo. José Trigo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Dong‐Wan, Byoung Chul Cho, Sang‐We Kim, et al.. (2024). Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study. Lung Cancer. 190. 107530–107530. 5 indexed citations

Trigo, José, Khalil Zaman, María Ángeles Sala, et al.. (2023). EP13.07-06 Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients. Journal of Thoracic Oncology. 18(11). S708–S709.

Trigo, José, Byoung Chul Cho, N. Girard, et al.. (2022). 20P Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S38–S39. 2 indexed citations

Harding, James J., Víctor Moreno, Yung‐Jue Bang, et al.. (2021). Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical Cancer Research. 27(8). 2168–2178. 116 indexed citations

Garrido, Pilar, Luis Paz‐Ares, Margarita Majem, et al.. (2021). LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 10(17). 5878–5888. 14 indexed citations

Gutierrez, Martin, Víctor Moreno, Kimberley M. Heinhuis, et al.. (2020). OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clinical Cancer Research. 27(2). 460–472. 58 indexed citations

Morgensztern, Daniel, Nina Karaseva, Enriqueta Felip, et al.. (2019). An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer. 136. 74–79. 19 indexed citations

Isla, Dolores, Javier de Castro, Rosario García‐Campelo, et al.. (2019). Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clinical & Translational Oncology. 22(5). 759–771. 11 indexed citations

Bauer, Todd M., Benjamin Besse, Alex Martínez‐Martí, et al.. (2019). Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC. Journal of Thoracic Oncology. 14(10). 1828–1838. 61 indexed citations

10.

Álvarez, Martina, et al.. (2019). Causes of death in patients with locally advanced head and neck cancer treated with radiotherapy and systemic therapy. BMC Cancer. 19(1). 1241–1241. 10 indexed citations

11.

Arce‐Lara, Carlos, Edurne Arriola, Paal Brunsvig, et al.. (2018). P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Pembrolizumab in Patients with Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S741–S741. 1 indexed citations

12.

Trigo, José, Alexandra Soliman, Lena C. Quilty, et al.. (2018). Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE. 13(1). e0190768–e0190768. 81 indexed citations

13.

Trigo, José, Alexandra Soliman, Lena C. Quilty, et al.. (2016). Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence. Journal of Addiction Medicine. 10(4). 274–279. 29 indexed citations

14.

Garcia, Philip, et al.. (2016). Words (Excluding Tãtle and Authors: 300) Title: Cost-Effectiveness Analysis of Nivolumab for the Treatment of Second-Line Advanced Squamous Non-Small Cell Lung Cancer (Nsclc) in Spain. Value in Health. 19(7). A732–A733. 1 indexed citations

15.

Foll, Bernard Le, Enoch Ng, Patricia Di Ciano, & José Trigo. (2015). Psychiatric Disorders as Vulnerability Factors for Nicotine Addiction: What Have We Learned from Animal Models?. Current topics in behavioral neurosciences. 24. 155–170. 8 indexed citations

16.

Lee, Bun-Hee, Jin-Pyo Hong, Jung-A Hwang, et al.. (2015). Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment. Psychiatry Research. 228(1). 95–99. 34 indexed citations

17.

Pérez-Ruiz, Elísabeth, Maximino Redondo, Martina Álvarez, et al.. (2012). Immunohistochemical expression of cyclooxygenase-2 in patients with advanced cancer of the larynx who have undergone induction chemotherapy with the intention of preserving phonation. Clinical & Translational Oncology. 14(9). 682–688. 7 indexed citations

18.

Trigo, José, Pilar Garrido, E. Felip Font, & Dolores Isla. (2010). SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clinical & Translational Oncology. 12(11). 735–741. 11 indexed citations

19.

Bellmunt, Joaquim, José Trigo, Emiliano Calvo, et al.. (2010). Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). The Lancet Oncology. 11(4). 350–357. 54 indexed citations

20.

Sessa, Cristiana, Sara Cresta, Thomas Cerny, et al.. (2006). Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Annals of Oncology. 18(3). 561–568. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact